BioCardia (BCDA) to Release Earnings on Wednesday

BioCardia (NASDAQ:BCDA) will likely be releasing its earnings data before the market opens on Wednesday, March 26th. Analysts expect BioCardia to post earnings of ($0.87) per share and revenue of $0.02 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

BioCardia Stock Up 1.5 %

BCDA stock opened at $2.66 on Wednesday. BioCardia has a 12 month low of $1.63 and a 12 month high of $6.41. The firm has a market cap of $12.19 million, a P/E ratio of -0.64 and a beta of 1.28. The company’s 50-day moving average price is $2.39 and its two-hundred day moving average price is $2.41.

Wall Street Analyst Weigh In

Several research firms have commented on BCDA. Alliance Global Partners raised shares of BioCardia from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of BioCardia in a report on Wednesday, December 18th.

Insider Activity at BioCardia

In related news, Director Simon H. Stertzer purchased 22,753 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The shares were bought at an average cost of $2.30 per share, with a total value of $52,331.90. Following the acquisition, the director now owns 40,602 shares of the company’s stock, valued at $93,384.60. This trade represents a 127.47 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders have purchased 26,353 shares of company stock valued at $60,585. 20.00% of the stock is owned by insiders.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.